On the production of pharmaceutical grade indium-111-chloride in the medical cyclotron from natural cadmium target and its use in formulation of diagnostic patient dose of .sup.111In-pentetreotide for imaging somatostatin receptor overexpression

A prototype, semi-automated, indigenous solid-target assembly has been developed to produce clinical grade .sup.111InCl.sub.3 from .sup.natCd targets. Fluka Monte Carlo code was used to estimate the optimum proton energy range for .sup.111Cd(p,n).sup.111In production route and suitable decay time to get high specific-activity of .sup.111In. The radiochemical purification and separation have been optimized using column chromatography separation method. The quality of .sup.111InCl.sub.3 has been established by radiolabeling of Pentetreotide yielding .sup.111In-Pentetreotide, in acceptable radiochemical purity (RCP), with expected biological efficacy in in-vitro and in-vivo models. Pre-clinical translation of .sup.111InCl.sub.3 in formulation of .sup.111In-Pentetreotide adds support toward its use as a clinical grade radiochemical.